Skip to main content
Equibles
FENC logo

FENC · Fennec Pharmaceuticals Inc.

Track FENC — free

Use FENC with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research FENC.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$11.62 +0.72 (+6.61%) At close · Nov 13
Russell 2000 member Rebalance outlook locked
Market Cap
$410.25M
Shares
35.31M
Volume · Nov 13 461.31K Avg daily vol (3M) 185.19K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$11.62 Open$11.12 Day$10.92–12.13 52W close$5.77–12.78 Avg vol 30d158K Short int454K · 1.3% of shares · 3.9d Short vol32% Last earningsNov 12, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 12

Up next

Next earnings call
Mar 23, 2027 Est · unconfirmed · in 18 wks
Q2 2026 earnings call transcript
call held Aug 11, 2026
Play latest call

Latest documents

2026
Nov 12
Quarterly report 10-Q FY2026 Q3, ended Sep 30
PEDMARK sales rise 67%, driving nine-month profitability

Fennec's nine-month PEDMARK sales rose $20,832, or 67%, to $51,697, while net income reached $6,814 versus a $4,954 loss. The Cipla settlement bars generic U.S. entry until September 1, 2033, or earlier under certain specified circumstances.

Revenue $19.61M ▲ 57.3% Net income $4.64M Diluted EPS $0.12
Read from the MD&A section
4 source passages
Fennec Pharmaceuticals Inc., a corporation existing under the laws of British Columbia, was originally formed under the name Adherex Technologies Inc. and subsequently changed its name on September 3, 2014. The Company recorded net product sales of $51,697 in the nine months ended September 30, 2026 compared to $30,865 in the comparable period in 2025, an increase of $20,832 or 67%, as the Company increased market penetration and access for PEDMARK® and expanded its focus to the adolescent and young adult (AYA) population. The year-over-year improvement was primarily driven by the shift from a net loss of $4,954 to net income of $6,814 as net product sales increased $20,832 year over year. On March 16, 2026, we announced that we had entered into a settlement and license agreement with Cipla Limited and Cipla USA, Inc. resolving the PEDMARK® patent litigation pending in the United States District Court for the District of New Jersey. Under the terms of the agreement, the lawsuit will be dismissed with each party bearing its own costs, and Cipla will not enter the U.S. market with its generic sodium thiosulfate product until September 1, 2033, or earlier under certain specified circumstances. Open the document at this passage
Sep 17
Current report 8-K
Other events AI summary on its way
Aug 13
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $17.87M ▲ 85.2% Net income $1.97M Diluted EPS $0.05
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$66.37M
Trailing 12 months
Net income (TTM)
$2.03M
Trailing 12 months
Revenue growth YoY
+57.3%
Year over year
Operating margin
5.6%
Trailing 12 months
P / E (TTM)
1,162.0
Trailing earnings · reciprocal yield 0.1%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$48.68M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+36.5%
Year over year · more shares
Price change (1Y)
+51.1%
Trailing year
Short interest
1.3%
Latest settlement · 3.9 days to cover
View all 125 metrics

Quarterly results

Revenue Net income Net loss
▼18.6% $7.92M −$1.99M '24 Q4* ▼65.5% $8.75M −$1.17M '25 Q1 ▲32.9% $9.65M −$3.15M '25 Q2 ▲78.7% $12.46M −$638,000 '25 Q3 ▲73.8% $13.78M −$4.79M '25 Q4* ▲72.6% $15.11M $201,000 '26 Q1 ▲85.2% $17.87M $1.97M '26 Q2 LATEST ▲57.3% $19.61M $4.64M '26 Q3

* Q4 derived as the full year minus Q1 to Q3.

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Bullish Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +24%
above
Price vs 50-day avg +9%
above
RSI (14) 61
neutral
MACD trend Positive
52-week position 83%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +16%
trailing
6-month return +17%
trailing
YTD return +51%
this year
Relative strength +17%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $11 › 200d $9 — 50d above 200d
Institutional flow Accumulating
84 of 106 funds reported for Sep 30 · net +1.3M sh shares · +15 new
Insider flow Distributing
Net -$146.2K over 90 days · 100% sells
Short interest Falling
1.29% of shares out · ▼ -6.8% MoM · 3.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
106 holders — near 3-yr high, broad support
Squeeze score 76
high risk · 0–100
Fundamentals
Weak
Revenue growth −6%
Y/Y
Gross margin 45%
expanding
EPS growth −1600%
Y/Y
Free cash flow $-12.5M
Valuation P/E 441.3
rich
Balance sheet $7.3M
net cash
Quant / Vol
risk profile
Very High
Volatility 68%
annualized · 1-yr
Max drawdown −36%
past year
ATR 6.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed May 14, 2026
Cash OPEX · 2026 $50M
Previous outlook earlier release · from the Earnings Call filed Mar 24, 2026

Still-open targets the latest release did not restate under the same label.

Cash operating expenses · 2026 $50M
Gross to net drop down · 2026 85%
Prior guidance period ended · from the Earnings Call filed Mar 24, 2026
Cash operating expenses · 2025 $35M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
0 · 4 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+24% Bullish
Price vs 50-day avg
+9% Bullish
RSI (14)
61 Neutral
MACD trend
Positive Bullish
52-week position
83% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $11 › 200d $9 — 50d above 200d
Institutional flow Accumulating
84 of 106 funds reported for Sep 30 · net +1.3M sh shares · +15 new
Insider flow Distributing
Net -$146.2K over 90 days · 100% sells
Short interest Falling
1.29% of shares out · ▼ -6.8% MoM · 3.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
106 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $6 Now $12 · 83% Range high $13
vs 200-day avg +24% vs 50-day avg +9%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted EBITDA non-GAAP $2.8M Three Months Ended June 30, 2026 filing —
GAAP → non-GAAP reconciliation
GAAP Net income $1.97M
-$287K Interest income
+$3K Interest expense
+$42K Provision for income taxes
+$0K Depreciation and amortization
-$710K Other revenue
+$1.77M Share based compensation expense
+$0K Unrealized loss on securities
+$6K Unrealized foreign exchange gain/(loss)
= Adjusted EBITDA $2.8M

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
FENC
Fennec Pharmaceuticals Inc.
this stock
$410.25M +50.9% -6.1% 441.3 1.3%
VRTX
Vertex Pharmaceuticals Inc
 $136.56B +18.8% +46.2% 34.7 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
 $98.84B +23.8% +20.8% 21.1 2.1%
MRNA
Moderna, Inc.
 $90.38B +657.4% +4.3% — 8.2%
CSLLY
Csl Ltd
 $66.05B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
117
% held
50.0%
Reported
84 of 106
Top holder
Rosalind Advisors, Inc.
Held Float
View
Held by Funds
Fund positions
79
View
Short & Settlement
Short Interest Falling
Shares short
454.5K
Days to cover
3.9d
Change
-33.1K sh
View
Short Volume
Short vol %
32%
As of
Nov 13, 2026
Short Total
View
Fails to Deliver
FTD shares
500
Value
$5.3K
As of
Sep 25, 2026
View
Off-Exchange
Off-exchange %
36.5%
Week of
Oct 5, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$146.2K
Buyers / Sellers
0 / 1
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$44.6M
Net income (FY)
$-9.7M
EPS diluted
$-0.34
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 12, 2026
This year
21

Fennec's nine-month PEDMARK sales rose $20,832, or 67%, to $51,697, while net income reached $6,814 versus a $4,954 loss. The Cipla settlement bars generic U.S. entry until September 1, 2033, or earlier under certain specified circumstances.

View
Proposed Sales
Value
$240.0K
Shares
20.0K
Filed
Nov 13, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 12, 2026
View
Investor Relations
Latest news
Fennec Pharmaceuticals Announces…
Published
Sep 17, 2026
View

Performance

5D 20D 120D MTD YTD
FENC +18.5% +16.4% +17.5% +13.5% +50.9%
SPY +2.6% -1.2% +0.5% -0.2% +10.6%
vs SPY +15.9% +17.6% +17.0% +13.7% +40.3%
Key facts CIK 1211583 CUSIP 31447P100 13F (30d) 87 filings 73 filers Visit website Investor relations